Dual SGLT1/2 inhibition with sotagliflozin: a pharmaceutical breakthrough in heart failure management and cardiometabolic risk reduction
Heart failure remains a global health crisis with high morbidity and mortality. Sotagliflozin, a first-in-class dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, offers a novel therapeutic approach. Its dual mechanism concurrently inhibits renal (SGLT2) and intestinal (SGLT1) glucose tr...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2026-01-01
|
| coleção: | Frontiers in Medicine |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1733918/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|